{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T07:02:58Z","timestamp":1790233378579,"version":"4.1.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-17017-8","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T07:15:54Z","timestamp":1789974954000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The effect of adding ovarian function suppression to adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive, HER2-positive breast cancer who have undergone neoadjuvant therapy: a single-center experience"],"prefix":"10.1186","volume":"26","author":[{"given":"Okan","family":"Aydin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hale Gulcin Yildirim","family":"Dogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sermin Dinc","family":"Sonusen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mert","family":"Erciyestepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet Emin","family":"Ozturk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asli","family":"Buyukkuscu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zehra Sucuoglu","family":"Isleyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayhan","family":"Erturk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"17017_CR1","doi-asserted-by":"publisher","unstructured":"Siegel Mph RL, Giaquinto AN, Ahmedin J, Dvm, Siegel RL. Cancer statistics, 2024, CA Cancer J. Jan. 2024;74(1):12\u201349. https:\/\/doi.org\/10.3322\/CAAC.21820.","DOI":"10.3322\/CAAC.21820"},{"key":"17017_CR2","doi-asserted-by":"publisher","unstructured":"Giaquinto AN et al. Nov., Breast cancer statistics 2024, CA Cancer J. Clin. 2024;74(6):477\u2013495 https:\/\/doi.org\/10.3322\/CAAC.21863.","DOI":"10.3322\/CAAC.21863"},{"key":"17017_CR3","doi-asserted-by":"publisher","unstructured":"Francis PA et al. Mar., Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT, J. Clin. Oncol. 2023;41(7):1370\u20131375 https:\/\/doi.org\/10.1200\/JCO.22.01065.","DOI":"10.1200\/JCO.22.01065"},{"key":"17017_CR4","doi-asserted-by":"publisher","unstructured":"Pagani O, et al. Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials. J Clin Oncol. Mar. 2022;41(7):1376. https:\/\/doi.org\/10.1200\/JCO.22.01064.","DOI":"10.1200\/JCO.22.01064"},{"key":"17017_CR5","doi-asserted-by":"publisher","unstructured":"Francis PA, et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. Jan. 2015;372(5):436\u201346. https:\/\/doi.org\/10.1056\/NEJMOA1412379.","DOI":"10.1056\/NEJMOA1412379"},{"key":"17017_CR6","doi-asserted-by":"publisher","unstructured":"Van MT, MacKelenbergh et al. Jun., Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer, J. Clin. Oncol. 2023;41(16):2998\u20133008. https:\/\/doi.org\/10.1200\/JCO.22.02241.","DOI":"10.1200\/JCO.22.02241"},{"key":"17017_CR7","doi-asserted-by":"publisher","unstructured":"Thomssen C, Balic M, Harbeck N, Gnant M. St. Gallen\/Vienna 2021: A Brief Summary of the Consensus Discussion on Customizing Therapies for Women with Early Breast Cancer. Breast Care. Apr. 2021;16(2):135. https:\/\/doi.org\/10.1159\/000516114.","DOI":"10.1159\/000516114"},{"key":"17017_CR8","doi-asserted-by":"publisher","unstructured":"Sukumar JS, et al. Real-world treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HR+\/HER2\u2009+\u2009breast cancer. Cancer Med. Jun. 2024;13(12):e7317. https:\/\/doi.org\/10.1002\/CAM4.7317.","DOI":"10.1002\/CAM4.7317"},{"key":"17017_CR9","doi-asserted-by":"publisher","unstructured":"Lian W, Li L, Hong C, Chen D. Impact of ovarian function suppression on prognosis in premenopausal patients with HR+\/HER2\u2009+\u2009early-stage breast cancer: a multi-center retrospective study. BMC Cancer. Dec. 2025;25(1):1\u20138. https:\/\/doi.org\/10.1186\/S12885-025-14774-W\/TABLES\/3.","DOI":"10.1186\/S12885-025-14774-W\/TABLES\/3"},{"key":"17017_CR10","doi-asserted-by":"publisher","unstructured":"Baek SY et al. Nov., Adding Ovarian Suppression to Tamoxifen for Premenopausal Women With Hormone Receptor-Positive Breast Cancer After Chemotherapy: An 8-Year Follow-Up of the ASTRRA Trial, J. Clin. Oncol. 2023;41(31):4864\u20134871. https:\/\/doi.org\/10.1200\/JCO.23.00557.","DOI":"10.1200\/JCO.23.00557"},{"key":"17017_CR11","doi-asserted-by":"publisher","unstructured":"Dackus GMHE, et al. Optimal adjuvant endocrine treatment of ER+\/HER2\u2009+\u2009breast cancer patients by age at diagnosis: A population-based cohort study. Eur J Cancer. Feb. 2018;90:92\u2013101. https:\/\/doi.org\/10.1016\/j.ejca.2017.11.010.","DOI":"10.1016\/j.ejca.2017.11.010"},{"key":"17017_CR12","doi-asserted-by":"publisher","unstructured":"Dieci MV, et al. Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive\/HER2-positive BC: analysis from the phase III randomized ShortHER trial. NPJ Breast Cancer. Dec. 2023;9(1). https:\/\/doi.org\/10.1038\/S41523-023-00509-2.","DOI":"10.1038\/S41523-023-00509-2"},{"key":"17017_CR13","doi-asserted-by":"publisher","unstructured":"Bae SJ et al. Dec., Ovarian Function Suppression in HR-Positive, HER2-Positive Breast Cancer: An Exploratory Analysis of the HERA Trial, Journal of the National Comprehensive Cancer Network, vol. 23, no. 12, pp. 539\u2013547, 2025, https:\/\/doi.org\/10.6004\/JNCCN.2025.7080","DOI":"10.6004\/JNCCN.2025.7080"},{"key":"17017_CR14","doi-asserted-by":"publisher","first-page":"104669","DOI":"10.1016\/j.breast.2025.104669","volume":"85","author":"A Shai","year":"2026","unstructured":"Shai A, et al. Adjuvant Ovarian Function Suppression and Aromatase Inhibitors in Premenopausal Patients with Hormone Receptor And Her2 Positive Breast Cancer, by Timing of Chemotherapy and Trastuzumab and Response to Neoadjuvant Therapy. Breast. 2026;85:104669. https:\/\/doi.org\/10.1016\/j.breast.2025.104669.","journal-title":"Breast"},{"key":"17017_CR15","doi-asserted-by":"publisher","unstructured":"Valenza C, Partridge AH, Regan MM. Optimizing adjuvant endocrine therapy in premenopausal patients with HER2-positive, hormone receptor-positive breast cancer. Breast: Official J Eur Soc Mastology. Feb. 2026;85:104696. https:\/\/doi.org\/10.1016\/J.BREAST.2026.104696.","DOI":"10.1016\/J.BREAST.2026.104696"},{"key":"17017_CR16","doi-asserted-by":"publisher","unstructured":"Ju J, et al. Prognostic factors and benefit populations of ovarian function suppression in premenopausal HR+\/HER2\u2009+\u2009early-stage breast cancer patients who received trastuzumab: Evidence from a real\u2010world study with long\u2010term follow\u2010up. Thorac Cancer. Feb. 2024;15(6):439. https:\/\/doi.org\/10.1111\/1759-7714.15211.","DOI":"10.1111\/1759-7714.15211"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-17017-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-17017-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-17017-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:36:26Z","timestamp":1790231786000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-17017-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["17017"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-17017-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"assertion":[{"value":"1 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective study was approved by the Ethics Committee of University of Health Sciences Prof. Dr. Cemil Tascioglu City Hospital (Approval No. 2025\/310). The requirement for informed consent was waived by the Ethics Committee because of the retrospective nature of the study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1140"}}